116 results
Page 4 of 6
6-K
gc08hwd uq1n74givu
7 Jun 21
FDA confirms NDA for Oleogel-S10 will not require an Advisory Committee Meeting
9:13am
424B3
flov1c k93s7k
3 Jun 21
Prospectus supplement
6:06am
424B3
utwecmv6f8
3 Jun 21
Prospectus supplement
6:06am
6-K
zkb5tvob7b1pyweckib
3 Jun 21
FDA Grants Priority Review for New Drug Application for Oleogel-S10 for the Treatment of Epidermolysis Bullosa
6:03am
424B3
qumipf4snde1o8xg
2 Jun 21
Prospectus supplement
10:10am
424B3
hg1ksdvl49v670sifnf
2 Jun 21
Prospectus supplement
10:09am
424B3
nesrwt3furdfsb 0f2
2 Jun 21
Prospectus supplement
10:08am
6-K
of0gc8
2 Jun 21
Amryt Announces FDA Acceptance of New Drug Application for Oleogel-S10 for the Treatment of Epidermolysis Bullosa
9:02am
6-K
x6zb9yoab0ayygw
5 May 21
Agreement and Plan of Merger
5:19pm
6-K
t5zucq
5 May 21
Amryt Reports Record Q1 2021 Financial and Operating Results
9:40am
6-K
4z7050u
5 May 21
Amryt Pharma to Acquire Chiasma, Inc. to Further Strengthen Global Leadership in Rare and Orphan Diseases
8:45am
20-F
a8qcrsk4bf76it2km7u
30 Apr 21
Annual report (foreign)
12:53pm
6-K
3d0 vrzx1g8ak
31 Mar 21
Amryt and Medison Pharma Sign Distribution Agreement for Myalepta® (metreleptin) in Canada
7:00am
424B3
ewemx tinzu95hy6t
4 Mar 21
Prospectus supplement
8:38am
6-K
9hnyvj0w0b46487a iub
4 Mar 21
Amryt Announces Record FY 2020 Results
8:20am
6-K
pu41ym zy3pu8
20 Jan 21
Amryt Receives Reimbursement Approval from NICE for Myalepta® (metreleptin) in England and Wales
6:30am
424B4
do20u52z5 ryxr
14 Jan 21
Prospectus supplement with pricing info
9:30am
F-1/A
ge774d bqo2a1n0jqb
12 Jan 21
Registration statement (foreign) (amended)
12:00am
F-1
EX-5.1
dyytlrs3wjv80e6no8tr
8 Jan 21
Registration statement (foreign)
4:58pm
F-1
lm3j5b
8 Jan 21
Registration statement (foreign)
4:58pm